These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

468 related articles for article (PubMed ID: 29534749)

  • 1. Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities.
    Porru M; Pompili L; Caruso C; Biroccio A; Leonetti C
    J Exp Clin Cancer Res; 2018 Mar; 37(1):57. PubMed ID: 29534749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent Advances in Targeting the EGFR Signaling Pathway for the Treatment of Metastatic Colorectal Cancer.
    Miyamoto Y; Suyama K; Baba H
    Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28368335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KRAS Mutations in Lung Adenocarcinoma: Molecular and Epidemiological Characteristics, Methods for Detection, and Therapeutic Strategy Perspectives.
    Guibert N; Ilie M; Long E; Hofman V; Bouhlel L; Brest P; Mograbi B; Marquette CH; Didier A; Mazieres J; Hofman P
    Curr Mol Med; 2015; 15(5):418-32. PubMed ID: 25941815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KRAS G12C Inhibitors in the Treatment of Metastatic Colorectal Cancer.
    Xiao A; Fakih M
    Clin Colorectal Cancer; 2024 Sep; 23(3):199-206. PubMed ID: 38825433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KRAS as a Therapeutic Target.
    McCormick F
    Clin Cancer Res; 2015 Apr; 21(8):1797-801. PubMed ID: 25878360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A small molecule approach to degrade RAS with EGFR repression is a potential therapy for KRAS mutation-driven colorectal cancer resistance to cetuximab.
    Lee SK; Cho YH; Cha PH; Yoon JS; Ro EJ; Jeong WJ; Park J; Kim H; Il Kim T; Min DS; Han G; Choi KY
    Exp Mol Med; 2018 Nov; 50(11):1-12. PubMed ID: 30459318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strategies to target energy metabolism in consensus molecular subtype 3 along with Kirsten rat sarcoma viral oncogene homolog mutations for colorectal cancer therapy.
    Wang G; Wang JJ; Yin PH; Xu K; Wang YZ; Shi F; Gao J; Fu XL
    J Cell Physiol; 2019 May; 234(5):5601-5612. PubMed ID: 30341899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EGFR Blockade Reverts Resistance to KRAS
    Amodio V; Yaeger R; Arcella P; Cancelliere C; Lamba S; Lorenzato A; Arena S; Montone M; Mussolin B; Bian Y; Whaley A; Pinnelli M; Murciano-Goroff YR; Vakiani E; Valeri N; Liao WL; Bhalkikar A; Thyparambil S; Zhao HY; de Stanchina E; Marsoni S; Siena S; Bertotti A; Trusolino L; Li BT; Rosen N; Di Nicolantonio F; Bardelli A; Misale S
    Cancer Discov; 2020 Aug; 10(8):1129-1139. PubMed ID: 32430388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. STAT3 signaling mediates tumour resistance to EGFR targeted therapeutics.
    Zulkifli AA; Tan FH; Putoczki TL; Stylli SS; Luwor RB
    Mol Cell Endocrinol; 2017 Aug; 451():15-23. PubMed ID: 28088467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KRAS: A Promising Therapeutic Target for Cancer Treatment.
    Wu HZ; Xiao JQ; Xiao SS; Cheng Y
    Curr Top Med Chem; 2019; 19(23):2081-2097. PubMed ID: 31486755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A systems mechanism for KRAS mutant allele-specific responses to targeted therapy.
    McFall T; Diedrich JK; Mengistu M; Littlechild SL; Paskvan KV; Sisk-Hackworth L; Moresco JJ; Shaw AS; Stites EC
    Sci Signal; 2019 Sep; 12(600):. PubMed ID: 31551296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-EGFR Therapy in Right-Sided Metastatic Colorectal Cancer: Right or Wrong?
    Weinberg BA
    J Natl Compr Canc Netw; 2018 Dec; 16(12):1547-1548. PubMed ID: 30545999
    [No Abstract]   [Full Text] [Related]  

  • 13. Emergence of KRAS-mutation in liver metastases after an anti-EGFR treatment in patient with colorectal cancer: Are we aware of the therapeutic impact of intratumor heterogeneity?
    Baretti M; Personeni N; Destro A; Santoro A; Rimassa L
    Cancer Biol Ther; 2018 Aug; 19(8):659-663. PubMed ID: 29580164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidermal growth factor receptor antagonists in colorectal cancer: emerging strategies for precision therapy.
    González NS; Marchese PV; Baraibar I; Ros J; Salvà F; Rodríguez M; Salvà C; Vaghi C; Alcaraz A; García A; Tabernero J; Élez E
    Expert Opin Investig Drugs; 2024 Jun; 33(6):613-625. PubMed ID: 38775361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting Mutant KRAS for Anticancer Therapy.
    Chen F; Alphonse MP; Liu Y; Liu Q
    Curr Top Med Chem; 2019; 19(23):2098-2113. PubMed ID: 31475898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.
    Therkildsen C; Bergmann TK; Henrichsen-Schnack T; Ladelund S; Nilbert M
    Acta Oncol; 2014 Jul; 53(7):852-64. PubMed ID: 24666267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multidimensional Screening Platform for Simultaneously Targeting Oncogenic KRAS and Hypoxia-Inducible Factors Pathways in Colorectal Cancer.
    Bousquet MS; Ma JJ; Ratnayake R; Havre PA; Yao J; Dang NH; Paul VJ; Carney TJ; Dang LH; Luesch H
    ACS Chem Biol; 2016 May; 11(5):1322-31. PubMed ID: 26938486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutral evolution of drug resistant colorectal cancer cell populations is independent of their KRAS status.
    Blagoev KB; Wilkerson J; Burotto M; Kim C; Espinal-Domínguez E; García-Alfonso P; Alimchandani M; Miettinen M; Blanco-Codesido M; Fojo T
    PLoS One; 2017; 12(10):e0175484. PubMed ID: 28981524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rationally co-targeting divergent pathways in KRAS wild-type colorectal cancers by CANscript technology reveals tumor dependence on Notch and Erbb2.
    Brijwani N; Jain M; Dhandapani M; Zahed F; Mukhopadhyay P; Biswas M; Khatri D; Radhakrishna VD; Majumder B; Radhakrishnan P; Thiyagarajan S
    Sci Rep; 2017 May; 7(1):1502. PubMed ID: 28473715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hope on the Horizon: A Revolution in KRAS Inhibition Is Creating a New Treatment Paradigm for Patients with Pancreatic Cancer.
    Aguirre AJ; Stanger BZ; Maitra A
    Cancer Res; 2024 Sep; 84(18):2950-2953. PubMed ID: 39279379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.